Fosun Pharma Joins Hands with Shenzhen FoF and Others to Establish a RMB5.0 Billion Biopharmaceutical Industry Fund, Jointly Promoting the High-Quality Development of Greater Bay Area’s Medical and Healthcare Industries

Release time:2024-03-12 Content sourced from: Page View:

On 12 March, Fosun Pharma announced that its controlled subsidiaries/companies, Fuxin Shenyao, Fosun Pharma (Shenzhen) and Shanghai Rehabilitation Equity Investment Fund Management Co., Ltd., together with seven investors including Shenzhen FoF, plan to jointly establish a target fund. The proposed fund-raising size of the target fund is RMB5.0 billion, with Shenzhen FoF contributing 50% of the subscription amount.

Fosun Pharma stated, this investment aims to, through further strengthening the sharing of recourses and advantages and cooperation with Shenzhen, expand the channels for enterprise cultivation in the healthcare industry (primarily focus on biopharmaceutical industry) in Shenzhen and reinforce the inventory and deployment of innovative technologies and products. The target fund will concentrate in Shenzhen and invest all proceeds in biopharmaceuticals, cells, genes and other industries, of which not less than 70% of the funds available for investment of the target fund shall be invested in biopharmaceuticals industry.


Shenzhen, as the core city of the Greater Bay Area, is a fertile ground for innovation and opening up. It also serves as a great example of China's pioneering efforts in reform and opening up. In the past two years, Shenzhen has introduced a series of measures to promote the development of biopharmaceutical and healthcare industries, and has continued to improve its industry policies. The RMB5.0 billion Shenzhen Biopharmaceutical Industry Fund is an industry fund specifically established to implement The Opinions of Shenzhen Municipal People's Government on Developing and Expanding Strategic Emerging Industry Clusters and Cultivating and Developing Future Industries and align with the “20+8” industry cluster development, so as to further promote the upgrading and development of the biopharmaceutical industry. In September 2023, Fosun Health Capital, initiated and established by its controlling shareholder Fosun Pharma, was selected as the management institution for the Shenzhen Biopharmaceutical Industry Fund.


Fosun Health Capital manages a number of renminbi-denominated funds, focusing on investments in the field of medicine and healthcare. It actively explores cutting-edge development in the global healthcare sector, precisely seizes investment opportunities, and covers different investment stages from early to mature stages, forming a unique model that places equal emphasis on scientific research and operational support, driven by both investment and industries. Leveraging its expertise in the medical and healthcare sectors, Fosun Health Capital will utilize the target fund as a platform to expand the channels for enterprise cultivation in the healthcare industry in Shenzhen and reinforce the inventory and deployment of innovative technologies and products.


After thirty years of development, Fosun Pharma, as a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, has established open innovation models such as independent R&D, cooperative development, license-in, and in-depth incubation. In addition, Fosun Pharma continues to enrich its innovative product pipelines, promotes the R&D and launch of many "world's first" and "China's first" innovative technologies and products, including the independently developed innovative anti-PD-1 monoclonal antibody drug HANSIZHUANG (serplulimab injection) and China's first approved CAR-T cell therapy product Yi Kai Da (ejilunsai injection), and leads the industry’s development through a unique open, global innovative R&D system.


In December 2023, Fosun Pharma established its Greater Bay Area headquarters in Shenzhen. In the future, Fosun Pharma will leverage Shenzhen, a city of innovation, to further increase investment in biomedicine, precision medicine and other fields, and continue to explore and improve the accessibility of innovative drugs and cutting-edge therapies, expanding China’s pharmaceutical innovation ecosystem and benefiting more patients in China and around the world.